Rat jugular vein hemostasis--a new model for testing antithrombotic agents.

Thromb Res

Pharmacological Laboratories of Luitpold-Werk, Chemisch-pharmazeutische Fabrik, München, Federal Republic of Germany.

Published: January 1989

Download full-text PDF

Source
http://dx.doi.org/10.1016/0049-3848(89)90116-3DOI Listing

Publication Analysis

Top Keywords

rat jugular
4
jugular vein
4
vein hemostasis--a
4
hemostasis--a model
4
model testing
4
testing antithrombotic
4
antithrombotic agents
4
rat
1
vein
1
hemostasis--a
1

Similar Publications

Chemotherapy is generally given by intravenous (IV) administration which provides higher bioavailability than other systemic routes. However, in the case of lung cancer, the pulmonary (INH) route is the other choice for inhalable formulations. In the study, biochemical and histological parameters of Cabazitaxel (CBZ) free (2 mg kg) and nanoparticle (NP) (2 mg kg CBZ equivalent) formulations are investigated after IV and INH administration in rats.

View Article and Find Full Text PDF

Dexmedetomidine alleviates acute kidney injury in a rat model of veno-arterial extracorporeal membrane oxygenation.

Intensive Care Med Exp

January 2025

Department of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou University, No. 80, Cuiyingmen, Chengguan District, Lanzhou, 730030, China.

Background: Although extracorporeal membrane oxygenation (ECMO) is an effective technique for life support, the incidence of acute kidney injury (AKI) during ECMO support remains high. Dexmedetomidine (DEX), which has been widely used for sedation during ECMO, possesses several properties that help reduce the occurrence of AKI. This study aimed to investigate the protective effect of DEX on kidney function during ECMO.

View Article and Find Full Text PDF

Background: The major concerns for patients who have acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 or sepsis and undergone successful venovenous extracorporeal membrane oxygenation (VV ECMO) include a low survival rate and an uncontrollable inflammatory response. This study aimed to introduce an inflammation-related ALI/ARDS rat model supported by VV ECMO that is more suitable for clinical application to assess the immune response and thereby further improve survival after VV ECMO.

Methods: Rats were randomly divided into three groups: the sham group, the lipopolysaccharide (LPS) group, and the LPS + ECMO group.

View Article and Find Full Text PDF
Article Synopsis
  • Vein grafts are critical for treating coronary artery disease, but neointimal hyperplasia (NIH) poses a significant challenge to their long-term success, with current identification and intervention methods being insufficient.
  • Researchers conducted a study using rats to observe the NIH development process after vein grafting while examining gene expression and specific markers related to NIH through various analytical methods.
  • The results showed that repair cells from outside the graft contribute significantly to NIH, with the protein Fhl1 playing a protective role against inflammation and cell proliferation, offering potential targets for improved treatments.
View Article and Find Full Text PDF
Article Synopsis
  • The study assesses the effectiveness of a new vein puncture method using ultrasound guidance for accessing the internal jugular vein in rats compared to the traditional tail vein method.
  • Twenty-four male Sprague-Dawley rats were divided into two groups to evaluate average puncture time, success rates, and imaging effects after administering ultrasound contrast agents.
  • Results showed that the ultrasound-guided method had a shorter average puncture time and higher initial success rates without causing adverse symptoms, suggesting it as a viable alternative for drug administration in animal experiments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!